GeoVax's Multi-Antigen COVID-19 Vaccine Shows Superior Immune Response in CLL Patients Compared to mRNA Vaccines
GeoVax's GEO-CM04S1 vaccine demonstrated significantly better immune response in chronic lymphocytic leukemia patients than standard mRNA vaccines, addressing a critical unmet need in immunocompromised populations.
GeoVax Labs, Inc. presented positive interim Phase 2 data for its COVID-19 vaccine candidate GEO-CM04S1 at the International Workshop on Chronic Lymphocytic Leukemia conference, showing superior performance compared to standard mRNA vaccines in immunocompromised patients. The data revealed that GEO-CM04S1 met the study's primary immune endpoint in chronic lymphocytic leukemia patients while the mRNA comparator did not, leading to an immediate shift in trial enrollment exclusively to the GEO-CM04S1 arm following recommendations from the Data Safety Monitoring Board.
The trial results highlight the significant clinical advantage of GeoVax's multi-antigen approach for vulnerable patient populations. Unlike first-generation vaccines that focus solely on the spike protein, GEO-CM04S1 utilizes a Modified Vaccinia Ankara vector platform that encodes both spike and nucleocapsid proteins of SARS-CoV-2. This design enables broader, cross-variant immune protection that appears particularly effective in patients with compromised immune systems, such as those with hematologic cancers who often respond poorly to conventional vaccines.
David Dodd, Chairman and CEO of GeoVax, emphasized the importance of these findings, stating that immunocompromised patients have not been adequately protected by current vaccines. The company's technology platform addresses a substantial commercial opportunity in a multi-billion dollar market segment where durable protection remains elusive. With millions of immunocompromised patients worldwide, including those with chronic lymphocytic leukemia and other hematologic malignancies, GEO-CM04S1 represents both a clinical advancement and significant market potential.
The vaccine candidate is currently being evaluated in three Phase 2 clinical trials, including as a primary vaccine for immunocompromised patients with blood cancers or post-transplant status, as a booster in CLL patients, and as a more robust COVID-19 booster in previously mRNA-vaccinated healthy adults. The favorable safety profile observed in the trial, with no grade 3 or higher adverse events reported, further supports the vaccine's potential for broader application in vulnerable populations who require enhanced protection against COVID-19 variants.